This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Questcor Teams With Child Neurology Foundation To Continue Funding Infantile Spasms Scientific Research

Stocks in this article: QCOR

HAYWARD, Calif., Dec. 3, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced that it is again partnering with the Child Neurology Foundation (CNF) to fund a $30,000 grant to support research into infantile spasms. Dr. Alex R. Paciorkowski of the University of Rochester Medical Center was selected by CNF as the recipient of its annual "Infantile Spasms Research Award."

"Questcor has an ongoing commitment to CNF and the entire infantile spasms community," said Steve Cartt, Chief Operating Officer for Questcor. "Further research into this devastating condition is imperative and we feel strongly about supporting initiatives that will advance the knowledge and treatment of infantile spasms."

Dr. Paciorkowski, whose application was reviewed by 10 of the nation's top child neurologists and then selected by the CNF Board of Directors, said he is focusing on genetic research related to infantile spasms.

"From the first English description by Dr. William James West in 1841, infantile spasms have posed a series of challenges for medical science," Dr. Paciorkowski said.  "We are still far from understanding the causes and optimal treatment of infantile spasms in many children."

He continued, "The Infantile Spasms Registry & Genetic Studies starts with the hypothesis that clearer understanding of the causes of infantile spasms should one day lead to the development of more effective therapies. In many patients, infantile spasms are due to mutations in genes that are important for patterning of the developing brain. From this observation, other genes that also cause infantile spasms may be 'neighbors' in the genetic blueprints that direct development of the brain. Finding these genes may lead to discovery of genetic pathways that in the future may be treatable with medicines – and help stop seizures sooner and with fewer side-effects. Using bioinformatics combined with next-generation sequencing, this work proposes to identify new genes and new pathways involved in infantile spasms. We have put together a highly collaborative international team of child neurologists, geneticists, and epilepsy experts. Our goal is to improve the care of children with infantile spasms by increasing the knowledge of the biology underlying this serious form of epilepsy."

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs